Objective: To evaluate the presenting signs and symptoms of dysphagia in patients with Zenker's diverticulum (ZD).
Method: All patients surgically treated for ZD over a 6-year period were identified. Charts were reviewed for dysphagia history and findings on fiberoptic endoscopic evaluation of swallowing (FEES) . Dysphagia symptoms and swallowing abnormalities were compared across groups based upon diverticulum size (small <1 cm, medium 1-3 cm, and large >3 cm).
Results: Forty-one patients were identified. ZD size was available in 39 cases (6 small, 18 medium, 15 large). Regurgitation symptoms were less frequent in patients with small (17%) compared to medium (70%) or large diverticula (73%) (P < .01). Similarly, esophagopharyngeal reflux (EPR) on FEES was less frequent in patients with small (17%) compared to medium (88%) and large diverticula (92%) (P < .01). EPR was present in all patients presenting for revision surgery (N = 9). In all cases, EPR resolved after successful treatment. Eighteen percent of all patients had evidence of pharyngeal weakness on FEES which did not change significantly on initial postoperative exam.
Conclusion: Dysphagia with EPR is predictive of a ZD larger than 1 cm, and may be useful in preoperative planning. EPR is also helpful in identifying patients with recurrent or residual symptomatic ZD following surgical treatment. Pharyngeal weakness is present in a subset of ZD patients.
Laryngology/Broncho-Esophagology Endoscopic Posterior Cricoid Expansion in Children
Mark E. Gerber, MD (presenter); Vikash K. Modi, MD; Robert F. Ward, MD; Verlia Gower; James R. Thomsen, MD Objective: To review our experience with endoscopic posterior cricoid split and costal cartilage graft placement in the management of pediatric bilateral vocal fold immobility (BVFI), posterior glottic stenosis (PGS), and subglottic stenosis (SGS).
Method: Multi-institutional retrospective case series of all patients treated with endoscopic posterior cricoid split and costal cartilage graft placement (EPCSCG) by any of the authors. Outcomes measured include: indications, complications, outcome.
Results: Twenty-six patients underwent EPCSCG. Age range at time of surgery was 1 month to 15 years. Overall, there was an excellent success rate with 25/26 either never requiring tracheostomy or achieving decannulation and 24/26 having adequate symptom control. The mean follow-up was 23.15 months. Sixteen patients had resolution of their symptoms. Fourteen patients had SGS in isolation or in combination with cricoarytenoid fixation, glottic stenosis or vocal fold immobility. Thirteen achieved decannulation and/or had resolution of preoperative symptoms. Three patients had isolated PGS or cricoarytenoid fixation with 2 achieving decannulation without additional procedures and the third decannulated after revision endoscopic division of a congenital anterior glottic web. Nine patients had isolated BVFI. Two of the 9 had failed prior laryngeal surgeries and 4 did not have tracheostomies at the time of their EPCSCG. Of these 9 patients, 7 had resolution of their airway symptoms without additional procedures.
Conclusion: Based on this experience, EPCSCG is worth consideration for the management of select pediatric patients with BVFI, PGS, and SGS.
Laryngology/Broncho-Esophagology Extraesophageal Reflux: Throat and Gastrointestinal Patients
Jason Powell, MBBS, MRCS (presenter); Ali Nikkar, MD; Jill Doyle; Janet A.
Wilson, MD, FRCS
Objective: Diagnosis and management of EER remains controversial. We have validated a reliable Comprehensive Reflux Symptom Scale (CReSS) incorporating 34 possible symptoms of EER and gastroesophageal reflux disease (GERD). We aimed to compare CReSS in healthy volunteers, throat clinic attenders, and a heterogeneous group referred for upper gastrointestinal (GI) endoscopy.
Method:
The CReSS was administered to 532 participants: 103 healthy volunteers, mean age 55 years, 39% male, 15% smokers; 175 throat clinic attenders, mean age 56 years, 37% male, 11% smokers; and 254 attenders for GI endoscopy, mean age 58 years, 41% male, 14% smokers. Regular recent antacid use was recorded.
Results: The mean CReSS total was 6.5 (SD 8.14) in volunteers, significantly lower (P < .001) than in throat 32.19 (SD 22.37) or GI patients 39.67 (SD 26.14) . CReSS totals were independent of age. All items were endorsed by at least 17% of throat patients, 30% of GI patients. The top symptoms in throat patients were throat clearing, hoarseness, globus, and mucus (62%-82% endorsement); 48 were on regular antireflux medication, and more of this subgroup had heartburn (75%), than of those who were not (38%). Eighty-six percent of the 148 GI patients on antireflux therapy also experienced heartburn, but only 56% of the remainder.
Conclusion: EER and GERD symptoms are incompletely understood and imperfectly responsive to antireflux therapy. The broad endorsement of all CReSS items by both patient groups supports recent evidence for an EER-GERD disease continuum. Back pain emerges as an under-recognized reflux symptom. Over-restrictive questionnaires reinforce speculative concepts of reflux disease.
